Rein Therapeutics Q2 net loss narrows on lower R&D spending

Rein said the current average analyst rating on the shares is "buy", with 2 strong buy or buy recommendations, 1 hold recommendation, and no sell or strong sell ratings.

The median 12-month price target is $6.00, about 661.9% above the stock's August 13 closing price of $0.79.

Rein Therapeutics said its second-quarter net loss narrowed year-over-year, helped by lower research and development spending.

The company reported a Q2 loss per share of $0.10, compared with the analyst consensus estimate of $0.17. Net loss came in at $6.38 million, versus expectations of $7.29 million. Income from operations was -$6.08 million, compared with the consensus estimate of -$7.04 million.

Rein completed a $57.5 million public offering to help fund its Phase 2 trial for in idiopathic pulmonary fibrosis, or .